Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer.
Breast cancer
Drug resistance
HER2
IL-6
Metastasis
Journal
Molecular biomedicine
ISSN: 2662-8651
Titre abrégé: Mol Biomed
Pays: Singapore
ID NLM: 9918283581406676
Informations de publication
Date de publication:
22 Jun 2022
22 Jun 2022
Historique:
received:
07
03
2022
accepted:
06
05
2022
entrez:
21
6
2022
pubmed:
22
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Acquisition of resistance to targeted therapies remains a major clinical obstacle for the HER2
Identifiants
pubmed: 35729402
doi: 10.1186/s43556-022-00079-y
pii: 10.1186/s43556-022-00079-y
pmc: PMC9213622
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Subventions
Organisme : NIAAA NIH HHS
ID : R21AA026675
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207751
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA207751
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA232589
Pays : United States
Organisme : NCI NIH HHS
ID : F99 CA264734
Pays : United States
Organisme : NCI NIH HHS
ID : R00CA198929
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Int J Cancer. 2014 Apr 15;134(8):1972-80
pubmed: 24150799
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Cancer Res. 2016 Nov 1;76(21):6410-6423
pubmed: 27488529
Breast Cancer Res Treat. 2021 Aug;189(1):177-185
pubmed: 34169393
J Biol Chem. 2012 May 25;287(22):18330-41
pubmed: 22493284
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4852-7
pubmed: 21368175
Cancers (Basel). 2019 May 28;11(6):
pubmed: 31141894
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
Cancer Res. 2004 Jun 1;64(11):3958-65
pubmed: 15173008
Oncogenesis. 2020 Feb 13;9(2):16
pubmed: 32054828
Oncotarget. 2016 Dec 13;7(50):83424-83436
pubmed: 27825137
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
Biochim Biophys Acta. 2012 Feb;1823(2):406-19
pubmed: 22015769
NPJ Breast Cancer. 2021 Jan 21;7(1):5
pubmed: 33479246
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Breast Cancer Res. 2011 Oct 03;13(5):R96
pubmed: 21967801
Biochem Biophys Res Commun. 2011 Apr 1;407(1):219-24
pubmed: 21377448
Trends Pharmacol Sci. 2015 Jan;36(1):32-40
pubmed: 25500711
Int J Biol Sci. 2020 Jul 19;16(14):2542-2558
pubmed: 32792856
Mol Cancer Res. 2014 Mar;12(3):408-420
pubmed: 24319068
Oncogene. 2021 Jan;40(2):322-333
pubmed: 33128042
Front Oncol. 2016 Jun 13;6:142
pubmed: 27379204
Cancer Res. 2019 Apr 15;79(8):1831-1843
pubmed: 30733195
Mol Cancer Ther. 2018 Jul;17(7):1441-1453
pubmed: 29695635
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Front Oncol. 2019 Nov 07;9:1186
pubmed: 31788449
Mol Cancer Ther. 2020 Apr;19(4):976-987
pubmed: 32241871
Oncogene. 2006 Oct 30;25(51):6887-99
pubmed: 17072334
Mol Cell. 2012 Aug 24;47(4):570-84
pubmed: 22819326
Crit Rev Oncog. 2012;17(1):1-16
pubmed: 22471661
Nat Rev Clin Oncol. 2020 Mar;17(3):133
pubmed: 31900443
Mol Cell Biol. 1990 May;10(5):2327-34
pubmed: 2183031
Cancer Lett. 2016 Nov 28;382(2):176-185
pubmed: 27597738